Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

China Pharma Holdings (CPHI) Interest & Investment Income (2016 - 2025)

China Pharma Holdings filings provide 16 years of Interest & Investment Income readings, the most recent being $213.0 for Q4 2025.

  • On a quarterly basis, Interest & Investment Income fell 84.04% to $213.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $2003.0, a 69.84% decrease, with the full-year FY2025 number at $2003.0, down 69.84% from a year prior.
  • Interest & Investment Income hit $213.0 in Q4 2025 for China Pharma Holdings, down from $294.0 in the prior quarter.
  • In the past five years, Interest & Investment Income ranged from a high of $6655.0 in Q1 2022 to a low of $213.0 in Q4 2025.
  • Median Interest & Investment Income over the past 5 years was $1157.0 (2022), compared with a mean of $1451.8.
  • Biggest five-year swings in Interest & Investment Income: skyrocketed 1539.16% in 2022 and later plummeted 85.76% in 2023.
  • China Pharma Holdings' Interest & Investment Income stood at $1412.0 in 2021, then decreased by 28.97% to $1003.0 in 2022, then surged by 152.24% to $2530.0 in 2023, then tumbled by 47.23% to $1335.0 in 2024, then plummeted by 84.04% to $213.0 in 2025.
  • The last three reported values for Interest & Investment Income were $213.0 (Q4 2025), $294.0 (Q3 2025), and $422.0 (Q2 2025) per Business Quant data.